Below are current clinical trials.1 studies in Corticobasal degeneration
(open studies only).
Filter this list of studies by location, status and more.
Jacksonville, Fla., Rochester, Minn.
Frontotemporal Lobar Degeneration (FTLD) is the neuropathological term for a collection of rare neurodegenerative diseases that correspond to four main overlapping clinical syndromes: frontotemporal dementia (FTD), primary progressive aphasia (PPA), corticobasal degeneration syndrome (CBS) and progressive supranuclear palsy syndrome (PSPS). The goal of this study is to build a FTLD clinical research consortium to support the development of FTLD therapies for new clinical trials. The consortium, referred to as Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL), will be headquartered at UCSF and will partner with six patient advocacy groups to manage the consortium. Participants will be evaluated at 14 clinical sites throughout North America and a genetics core will genotype all individuals for FTLD associated genes.
Aug. 23, 2017
- Factor SA, et al. Corticobasal degeneration. http://www.uptodate.com/home. Accessed Oct. 13, 2016.
- Riggin EA. Decision Support System. Mayo Clinic, Rochester, Minn. July 1, 2016.
- NINDS corticobasal degeneration information page. National Institute of Neurological Disorders and Stroke. http://www.ninds.nih.gov/disorders/corticobasal_degeneration/corticobasal_degeneration.htm. Accessed Oct. 13, 2016.
- Daroff RB, et al. Neurodegenerative disease processes. In: Bradley's Neurology in Clinical Practice. 7th ed. Philadelphia, Pa.: Saunders Elsevier; 2016. https://www.clinicalkey.com. Accessed Oct. 13, 2016.
- Budson AE, et al. Corticobasal degeneration. In: Memory Loss, Alzheimer's Disease, and Dementia. 2nd ed. Philadelphia, Pa.: Elsevier; 2016. http://www.clinicalkey.com. Accessed Oct. 13, 2016.
- Graff-Radford N (expert opinion). Mayo Clinic, Rochester, Minn. Oct. 25, 2016.